The Ability of Preoperative Serum CA-125 to Predict Optimal Primary Tumor Cytoreduction in Stage III Epithelial Ovarian Carcinoma
- 1 May 2000
- journal article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 77 (2), 227-231
- https://doi.org/10.1006/gyno.2000.5749
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Neoadjuvant Chemotherapy for Advanced Ovarian Cancer: Long-Term SurvivalGynecologic Oncology, 1999
- Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Carcinoma: A Retrospective Analysis of 285 PatientsGynecologic Oncology, 1998
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- The Effect of Debulking Surgery after Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian CancerNew England Journal of Medicine, 1995
- Epithelial Ovarian Carcinoma: Principles of Primary SurgeryGynecologic Oncology, 1994
- The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinomaAmerican Journal of Obstetrics and Gynecology, 1994
- The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group studyGynecologic Oncology, 1992
- Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1989
- Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: Relevance for early detection of ovarian cancerInternational Journal of Cancer, 1988
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983